Working Memory Training in Huntington's Disease

Status Completed

Clinical Trial Summary

There is a paucity of investigation into effective interventions to enhance cognitive function and/or mitigate cognitive decline in individuals with Huntington disease (HD). This study targeted working memory (WM), which is the ability to actively hold information in the mind in order to perform complex mental tasks, given reports of WM dysfunction in patients with HD. The investigators examined the feasibility of conducting a 5-week WM training program (Cogmed). Patient adherence and treatment tolerance were assessed. In addition, preliminary evidence for the efficacy of this training program on targeted cognitive abilities was examined. Nine patients with pre-manifest or early stage HD underwent training. Patients were assessed before the intervention and one week after completion.

Clinical Trial Description

Huntington disease (HD) is associated with a variety of cognitive deficits, with prominent difficulties in working memory (WM). WM deficits are notably compromised in early-onset and prodromal HD patients. This study aimed to determine the feasibility of a computer-ized WM training program (Cogmed QM), novel to the HD population. Nine patients, aged 26-62, with early stage HD underwent a 25-session (5 days/week for 5 weeks) WM training program (Cogmed QM). Training exercises involved the manipulation and storage of verbal and visuospatial information, with difficulty adapted as a function of individual performance. Neuropsychological testing was conducted before and after training, and performance on criterion WM measures (Digit Span and Spatial Span) and near-transfer WM measures (Symbol Span and Auditory WM) were evaluated. Post-training inter-views about patient experience were thematically analyzed using NVivo software. Seven of nine patients demonstrated adherence to the training and completed all sessions within the recommended timeframe of 5 weeks. All adherent patients reported that they found training helpful (n=7), and almost all felt that their memory improved (n=6). Compared to baseline scores, patients showed significant improvement on the neuropsychological measures of verbal WM, including Digit Span (p = .047) and Auditory WM (p = .041). This pilot study provides support for feasibility of computerized WM training in early-stage patients with HD. Results suggest that HD patients can improve WM with intensive training, though a full-scale intervention project is needed to understand the reliability of changes over time. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02926820
Study type	Interventional
Source	York University
Contact
Status	Completed
Phase	N/A
Start date	February 2015
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04120493` - Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease	Phase 1/Phase 2
Completed	`NCT02956148` - Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers	Early Phase 1
Terminated	`NCT02494778` - A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease	Phase 2
Completed	`NCT02208934` - Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers	Phase 1
Completed	`NCT02216474` - Brain Stimulation in Movement Disorders	N/A
Completed	`NCT02197130` - Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease	Phase 2
Completed	`NCT01806896` - Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease	Phase 2
Completed	`NCT01502046` - Neuroprotection by Cannabinoids in Huntington's Disease	Phase 2
Terminated	`NCT00712426` - Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Phase 3
Completed	`NCT00670709` - Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Completed	`NCT00029874` - Minocycline in Patients With Huntington's Disease	Phase 1/Phase 2
Terminated	`NCT02231580` - Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients	Phase 2
Completed	`NCT02215616` - A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod	Phase 2
Not yet recruiting	`NCT02551705` - Functional Imaging of Social Cognition in Premanifest Huntington's Disease	N/A
Active, not recruiting	`NCT02101957` - Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)	Phase 2/Phase 3
Completed	`NCT00975481` - A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users	Phase 1
Completed	`NCT00990613` - A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin	Phase 1
Completed	`NCT01521832` - Escalating Dose Study in Healthy Volunteers With SEN0014196	Phase 1
Completed	`NCT00387270` - Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT00095355` - Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease	Phase 2